Industry Responds to FDA’s Quality Metrics Initiative with Proposal to Report Trends, not Values
This article was originally published in The Gold Sheet
Executive Summary
Industry, FDA explore why manufacturers should report absolute value of quality metrics, not just the trends. FDA’s Woodcock suggests potential reward of reduced inspections by not only FDA, but also by other inspectorates.
You may also be interested in...
After Recusal, Schnedar Leaving CDER Compliance Office
Cynthia Schnedar decides to leave several weeks after FDA determined that her husband's promotion could create conflicts of interest.
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
CDER’s Woodcock says the new database will drive risk-based inspection decisions.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.